The Phase 3 trial will investigate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1 HCV.
The company will recruit around 1,875 patients in three Phase 3 trials across the world.
Boehringer Ingelheim Medical Affairs executive director Peter Piliero said they are pleased to have begun enrolling patients at North American trial sites as they continue development of BI 201335.
"We look forward to initiating additional trials later this year in more patient populations, including HCV-HIV coinfected patients, as we continue to advance our HCV portfolio," Piliero said.